OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
Rhea-AI Summary
OS Therapies (NYSE: OSTX) said the FDA elevated its Type D biomarker meeting for OST-HER2 to a Type B pre-BLA meeting, shifting discussions toward Accelerated Approval. The company is targeting completion of its clinical data submission by end of Q1 2026 and seeks Accelerated Approval in H2 2026.
OST-HER2 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations; a Priority Review Voucher sale comparable transaction was reported at $205 million in February 2026.
Positive
- FDA elevated meeting to Type B pre-BLA, signaling regulatory progress
- Company targets clinical data submission completion by end of Q1 2026
- OST-HER2 has Orphan Drug, Fast Track, and Rare Pediatric Disease designations
- Priority Review Voucher market comparables: reported sale at $205M (Feb 2026)
Negative
- Confirmatory randomized Phase 3 must be commenced before Accelerated Approval, a regulatory prerequisite
- Accelerated Approval timing depends on FDA acceptance and trial start; company targets H2 2026 which may be optimistic
News Market Reaction – OSTX
In the Mar 9 session, OSTX gained 8.92%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.1% during that session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.7x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Regulatory update | Positive | -0.8% | Global regulatory update and BLA timelines for OST-HER2 submissions. |
| Feb 04 | Policy/PRV update | Positive | -5.7% | Reauthorization of PRV program preserving OST-HER2 voucher eligibility. |
| Feb 02 | BLA initiation | Positive | +2.2% | Initiation of U.S. BLA filing and rolling review request for OST-HER2. |
| Jan 15 | Clinical data | Positive | -5.8% | Positive Phase 2b biomarker data linking biomarkers with overall survival. |
| Jan 14 | Subsidiary IPO plan | Positive | +0.7% | OS Animal Health S-1 filing and contemplated equity distribution to OSTX holders. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OST-HER2 regulatory and clinical updates have often seen mixed to negative next-day price reactions despite generally positive news tone.
Over the past months, OS Therapies has steadily advanced OST-HER2. On Jan 15, positive Phase 2b biomarker data were reported, followed by a BLA filing initiation on Feb 2 and a global regulatory update on Feb 17. Earlier, an S-1 filing for OS Animal Health was announced on Jan 14, and policy support for the PRV program was highlighted on Feb 4. Despite positive regulatory and clinical momentum, several of these updates were followed by negative price reactions, making today’s constructive move more aligned with the underlying progress.
Key Terms
type b pre-bla meeting regulatory
biologics license application (bla) regulatory
accelerated approval regulatory
orphan drug designation regulatory
fast track designation regulatory
rare pediatric disease designation regulatory
priority review voucher regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions
OS Therapies on track to complete clinical data submission by the end of Q1 2026
New York, New York--(Newsfile Corp. - March 9, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided an update regarding ongoing conversations with the United States Food & Drug Administration (FDA) with regards to its ongoing Biologics License Application (BLA) submission under the Accelerated Approval Program (Accelerated Approval) for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. FDA elevated OS Therapies' Type D Biomarker Meeting to a Type B pre-BLA Meeting, expected to occur shortly after the Company completes submission of its clinical data package to the agency, targeted for the end of the first quarter of 2026.
"We credit FDA with taking decisive action to help advance Accelerated Approval discussions regarding OST-HER2 for pediatric cancer patients with osteosarcoma," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "With the biomarker analysis complete, and patent filings in process, we are poised to deliver data to the agency that we believe represents surrogate clinical efficacy sufficient to enable our ongoing BLA submission. Following key meetings with Key Opinion Leaders over the last few weeks, many of whom treated patients in our clinical trial, we believe we now have a clear path forward to establish confirmatory randomized Phase 3 trial that is required to have a commenced prior to being granted Accelerated Approval in the United States."
OST-HER2 has received FDA Orphan Drug Designation (ODD) and Fast Track Designation from the FDA & EMA and has also received Rare Pediatric Disease Designation (RPDD) from the FDA. Under the RPDD program, if the Company receives Accelerated Approval in the United States, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to sell. The most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in listeria-based cancer immunotherapies. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates receiving a Biologics Licensing Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving conditional Marketing Authorisations from the U.K.'s Medicines and Healthcare products Regulatory Agency and the European Medicines Agency for OST-HER2 in 2026. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. The Company also anticipates reading out data from a Phase 1b study of OST-504 in castration resistant prostate cancer in the first half of 2026.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
media@ostherapies.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287699